About Bioheng Therapeutics
Bioheng Therapeutics, established in 2017, is a clinical-stage biotech company specializing in allogeneic “off-the-shelf” universal CAR-T therapies. Focused on innovative cell therapy platforms, Bioheng addresses critical unmet needs in oncology and autoimmune diseases. In March 2022, Bioheng’s CTA101 became the first UCAR-T IND approved in China, and its CD7-targeted UCAR-T, CTD40X, received Orphan Drug Designation from the U.S. FDA. Built on the ANSWER® platform, these cutting-edge CAR-T therapies demonstrate high efficacy and safety in clinical trials, significantly advancing cancer treatment.
Bioheng has secured nearly 700 million yuan in funding, including 520 million yuan from Hillhouse Venture Capital, Decheng Capital, and Octagon Capital. The company holds 49 core patents and has been recognized as a “Cultivating Unicorn Enterprise” and “Nezha Enterprise,” alongside other prestigious honors in Jiangsu and Nanjing.
Digital Transformation with iLabPower Project Management (PM) and Electronic Lab Notebook (ELN)
To enhance its R&D efficiency, Bioheng partnered with Neotrident to deploy iLabPower Project Management (PM) and Electronic Lab Notebook (ELN) systems. These platforms revolutionized Bioheng’s approach to R&D management by integrating project planning, task allocation, and experiment documentation. The iLabPower PM system allows real-time tracking of project progress, resource allocation, and team collaboration, while the ELN platform provides structured and secure data capture for all experimental activities, from synthesis to biotesting.
Key Benefits of iLabPower PM and ELN Integration
- Fast Implementation: Leveraging iLabPower’s streamlined configuration, the entire implementation—including process mapping, training, and performance qualification (PQ) verification—was completed in just two months, significantly faster than traditional methods.
- Seamless Data Flow: The integration of iLabPower ELN enables comprehensive electronic experimental records and sample tracking across core R&D departments, ensuring a smooth flow of data and robust feedback mechanisms.
- Regulatory Compliance: The Validation Cloud SaaS platform supports compliance with GXP standards, providing robust data integrity, traceability, and security across all R&D processes.
- Increased R&D Efficiency: By adopting iLabPower PM and ELN, Bioheng significantly improved R&D workflow efficiency, supporting sustainable growth and enhancing innovation capacity.
Pioneering CAR-T Innovation with Digital Solutions
Bioheng’s innovative “off-the-shelf” CAR-T therapies set a new benchmark in cell therapy, overcoming challenges such as high costs and production delays. Leveraging iLabPower’s PM and ELN systems, Bioheng accelerates its R&D processes, enabling rapid scale-up and greater accessibility of immune cell therapies.
